摘要
目的 探究拉米夫定和重组人干扰素α-2b联合治疗慢性乙型病毒性肝炎的临床疗效和安全性。方法 选择2012年5月~2013年6月于我院接受治疗的86例已确诊为慢性乙型病毒性肝炎的患者作为研究对象,所有患者均给予常规的护肝治疗并随机分为实验组和对照组。其中对照组患者40例,在常规治疗的基础上给予拉米夫定进行治疗;实验组患者46例,实验组患者在此基础上联合应用重组人干扰素α-2b进行治疗,两组患者的治疗疗程均为48周,观察两组患者治疗后血常规、血清HBV复制指标和肝功能的变化及不良反应情况。结果 治疗24周后,两组患者临床指标丙氨酸氨基转移酶（ALT）复常率、乙肝病毒脱氧核糖核酸（HBV-DNA）阴转率、乙型肝炎病毒e抗原（HBeAg）阴转率、HBeAg转化率比较,差异无统计学意义（P〉0.05）;治疗48周后,以上临床指标比较,差异有统计学意义（P〈0.05）,实验组的总有效率显著高于对照组（P〈0.05）。两组患者不良反应发生率比较,差异无统计学意义（P〉0.05）。结论 拉米夫定和重组人干扰素α-2b联合治疗慢性乙型病毒性肝炎疗效显著,且优于单纯应用拉米夫定治疗,无明显不良反应,安全性可靠,值得临床推广应用。
Objective To explore the clinical effect and safety of lamivudine combined with recombinant human interferon α-2b in the treatment of chronic viral hepatitis B. Methods Eighty-six patients diagnosed as chronic viral hepatitis B from May 2012 to June 2013 in our hospital were selected as research objects.All patients were treated with conventional hepatic protection and randomly divided into experimental group and control group.In the control group（n= 40）,on the basis of the conventional treatment,lamivudine was provided,while in the experimental group （n=46）,on the basis of the control group,recombinant human interferon α-2b was added.The courses of treatment lasted 48 weeks.The blood routine examinations,serum HBV replication,changes of liver function,and adverse reactions between groups was observed respectively. Results After 24 hours treatment,the normalizing rate of glutamic transaminase,negative conversion rates of HBV-DNA and HBeAg,and percent conversion of HBeAg didn＇t display statistical differences between two groups（P〉0.05）.After 48 weeks treatment,these clinical indexes mentioned above indicated statistical differences,the total effective rate in experimental group was much higher than that in control group （P〈0.05）.Incidence of adverse reactions didn＇t show a significant difference （P〉0.05）. Conclusion Combination of lamivudine and recombinant human interferon α-2b obtains a remarkable effect on treating chronic viral hepatitis B.Tbe effect is better than that only by lamivudine.It has no obvious adverse reaction and is with a reliable security,which is worthy of clinical promotion.
出处
《中国当代医药》
2015年第27期73-75,共3页
China Modern Medicine
基金
广东省湛江市财政资金科技专项竞争性分配项目(2014A404)
